By 
Understanding how a medication works provides the basis for evaluating claims about it accurately – both the genuine concerns and the unfounded ones. NexGard flea treatment NZ built its reputation on afoxolaner, an active compound that belongs to the isoxazoline class of parasiticides. Afoxolaner’s mechanism is both highly specific to invertebrates and well-understood at the molecular level, which is why it provides such consistent and rapid efficacy against fleas while being well-tolerated in dogs at therapeutic doses.
GABA Receptors and the Flea Nervous System
Afoxolaner works by targeting GABA (gamma-aminobutyric acid) gated chloride ion channels in the nervous systems of insects and arachnids. In a normally functioning flea nervous system, GABA binds to these channels, opening them to allow chloride ions into the nerve cell – creating an inhibitory effect that prevents excessive, uncontrolled nerve firing. This regulatory function keeps the flea’s neurological activity within normal bounds.
Afoxolaner binds to these same channels and blocks them – but in a way that GABA cannot overcome. The result is the opposite of the normal inhibitory effect: nerve cells fire without appropriate inhibitory control, creating an excitatory crisis in the flea’s nervous system. Uncontrolled nerve firing causes paralysis, convulsions, and rapid death. The flea cannot adapt to or recover from this state at effective drug concentrations.
Why It Is Safe in Dogs
The selectivity of afoxolaner for invertebrate rather than mammalian nervous systems is what makes it safe in dogs. Mammals have GABA receptors too, but they differ in structure from the invertebrate versions in ways that significantly reduce afoxolaner’s binding affinity. At the concentrations present in a correctly dosed dog, afoxolaner does not reach levels that meaningfully affect mammalian GABA receptors.
This selectivity is not unique to afoxolaner – it is characteristic of the isoxazoline class and is the pharmacological foundation for the safety records of all products in this group. The difference between invertebrate and mammalian receptor structures means the effective dose for flea kill is well below the level at which mammalian receptor effects would become apparent. This separation between efficacy and toxicity doses is the definition of a favourable safety margin.
Systemic Distribution: Whole-Body Protection
After the chewable tablet is ingested, afoxolaner is absorbed through the gastrointestinal tract and distributed through the bloodstream, reaching maximum plasma concentrations within hours. Because the distribution is systemic – via the blood – every part of the dog’s body receives exposure to afoxolaner. Fleas that bite anywhere on the dog ingest the compound in the blood meal and receive a lethal dose.
This whole-body systemic protection is a specific advantage over some topical treatments where distribution may be uneven – concentrated near the application site with potentially lower concentrations in areas like the legs and feet. With NexGard, there is no region of the dog where protection is absent or reduced. Every flea, wherever it bites, is exposed to the same lethal concentration.
Breaking the Flea Lifecycle
The speed of kill with afoxolaner has significant implications beyond reducing the dog’s immediate discomfort. A female flea that does not survive long enough to reproduce cannot lay eggs. NexGard kills fleas before the completion of their reproductive cycle, disrupting the lifecycle at the source and preventing the environmental infestation from being replenished with new generations.
Dogs consistently treated with NexGard in a household will typically not develop significant environmental flea infestations over time, even if newly emerging environmental fleas continue to reach the dog, because those fleas keep arriving and keep dying before they can lay viable eggs. The environmental population gradually collapses as its reproductive cycle is continuously interrupted.
Monthly Pharmacokinetics
Afoxolaner’s monthly duration reflects its metabolic pathway – it is processed and eliminated over approximately thirty days, requiring monthly re-dosing to maintain protective concentrations. This contrasts with fluralaner in Bravecto, which has stronger fat-tissue affinity that extends its duration to twelve weeks. Neither duration is pharmacologically superior – they simply reflect different molecular properties that suit different treatment schedules.
For New Zealand dog owners using NexGard as part of a year-round programme, sourcing from an authorised pet supply NZ retailer ensures consistent product quality and appropriate storage. The efficacy of afoxolaner depends on the integrity of the active compound, which in turn depends on the product having been stored correctly from manufacture through to administration.
Practical Implications for NZ Dog Owners
The mechanistic understanding of how afoxolaner works translates directly into practical guidance for New Zealand dog owners. Because the compound works systemically, water exposure has no effect on its efficacy – the active compound is in the bloodstream, not on the coat surface. Because it kills quickly, newly-emerged environmental fleas die within hours of reaching the treated dog. Because it requires monthly re-dosing due to its pharmacokinetics, consistent timing is important for maintaining protective concentrations without gaps.
New Zealand dog owners using NexGard as part of a year-round flea management programme should purchase from an authorised
pet supply NZ
retailer to ensure product quality and appropriate storage conditions. The efficacy of afoxolaner is dependent on the integrity of the active compound in the formulation.
Getting the Right Product for Your New Zealand Pet
New Zealand pet owners have access to a well-regulated market of veterinary parasite prevention products that has improved significantly in both breadth and accessibility over the past decade. The combination of prescription-only status for the most effective treatments – ensuring veterinary oversight – and the growth of authorised online retailers – ensuring competitive pricing – means that effective, consistent parasite prevention is both medically supported and economically accessible.
The practical framework for most New Zealand pet owners is straightforward: establish the appropriate product for your specific animal at the annual veterinary check-up, obtain the prescription, and source the year’s supply from an authorised pet supply NZ retailer. Maintain the schedule consistently using whatever reminder system works reliably for your household, treat all animals in the household simultaneously, and include environmental management when addressing any existing infestation. This approach provides the best possible parasite protection for your pet without unnecessary complexity or cost.
When to Review Your Current Approach
Parasite management should be reviewed at any annual veterinary check-up, any time a pet changes weight significantly enough to affect its weight-range formulation, any time a new pet joins the household and requires integration into the existing programme, and any time a product appears to be failing – whether through apparent treatment failure, unexpected adverse effects, or a change in the pet’s health circumstances that might create new product considerations.
The New Zealand veterinary profession is well-informed about local parasite prevalence, regional heartworm risk, and the evidence base for current product recommendations. Your local vet’s advice is more specifically relevant to your area and your individual animal than any general information source – including this one. Use annual check-ups as the opportunity to validate that your current approach remains appropriate, and use authorised pet supply NZ retailers for cost-efficient routine supply between those annual reviews.
Comments